CLDF Title
Home | Contact Us | Bookmark
    HCC   HE   HRS   NASH   PBC   THROMBOCYTOPENIA  
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
 
Back  
 
Reuters Health Information: Liver injury common with COVID-19

Liver injury common with COVID-19

Last Updated: 2020-03-11

By Will Boggs MD

NEW YORK (Reuters Health) - As many as 54% of patients with COVID-19 develop liver enzyme abnormalities during disease progression, according to a brief review.

Liver impairment was reported in up to 60% of patients with Severe Acute Respiratory Syndrome (SARS) and in patients infected with the Middle East respiratory syndrome coronavirus, both of which share genome sequence similarity with SARS coronavirus 2 (SARS-CoV-2), which is responsible for COVID-19.

Dr. Fu-Sheng Wang and colleagues from National Clinical Research Center for Infectious Diseases, Beijing, China used data from seven case studies and from The Fifth Medical Center of PLS General Hospital, Beijing, China to evaluate how the liver is affected in COVID-19.

Overall, 2-11% of patients with COVID-19 had liver abnormalities, and 14-53% of COVID-19 cases had abnormal levels of alanine aminotransferase and aspartate aminotransferase during disease progression.

Patients with severe COVID-19 appeared to have higher rates of liver dysfunction, and symptomatic patients were more likely to have elevated liver enzymes compared with patients with subclinical disease, according to the online report in The Lancet Gastroenterology and Hepatology.

Gamma-glutamyl transferase, a diagnostic biomarker for cholangiocyte injury, was elevated in 54% of COVID-19 patients hospitalized at Fifth Medical Center, whereas only one patient (1.8%) had elevated alkaline phosphatase levels.

Elsewhere, pathological analysis of liver tissue from a patient who died from COVID-19 did not find viral inclusions in the liver.

Chronic liver disease affects about 300 million people in China, but so far the interaction between existing liver disease and COVID-19 has not been studied.

"Considering their immunocompromised status, more intensive surveillance or individually tailored therapeutic approaches is needed for severe patients with COVID-19 with pre-existing conditions such as advanced liver disease, especially in older patients with other comorbidities," the authors conclude. "Further research should focus on the causes of liver injury in COVID-19 and the effect of existing liver-related comorbidities on treatment and outcome of COVID-19."

Dr. Hongcui Cao from The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, who recently reported the clinical characteristics of imported cases of COVID-19 in Jiangsu province, told Reuters Health by email, "This comment article presented a novel idea that hepatocytes and cholangiocytes might be potential targets during SARS-CoV-2 infection, as angiotensin-converting enzyme 2 (ACE2), which serves as the viral receptor, is detected (even though at low levels) in endothelial cells, occasional bile ducts, and perivenular hepatocytes in healthy livers."

"Meanwhile, previous researchers have stated that chronic liver injury in rats and humans upregulates ACE2," she said. "Combining this evidence, patients with pre-existing liver conditions might be more susceptible to SARS-CoV-2."

"Patients with pre-existing liver dysfunctions should be more carefully monitored and be given liver protective drugs when needed," Dr. Cao said. "For patients with severe liver damage, artificial liver blood purification system is recommended. This system is capable of removing inflammatory mediators and blocking cytokine storm that are potentially hazardous to liver and other organs, and simultaneously balances the electrolyte and acid-base level of body fluid. This system has previously shown improved therapeutic efficacy for treating SARS patients."

Dr. Wang did not respond to a request for comments.

SOURCE: https://bit.ly/339DVFh The Lancet Gastroenterology and Hepatology, online March 4, 2020.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2020 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.